Drug Search Results
More Filters [+]

PGN-650

Alternative Names: pgn-650, pgn650, pgn 650
Latest Update: 2017-07-11
Latest Update Note: Clinical Trial Update

Product Description

PGN650 is a F(ab')2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29037107/)

Mechanisms of Action: Phosphatidylserine Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Avid Bioservices
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PGN-650

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PPHM 1201

P1

Terminated

Oncology Solid Tumor Unspecified

2016-05-01

Recent News Events

Date

Type

Title